8-K Announcements
6Material company update
May 20, 2026·SEC
Material company update
Feb 6, 2026·SEC
Material company update
Dec 12, 2025·SEC
Immunovant, Inc.(IMVT)Earnings, Financials & Key Ratios
IMVT•NASDAQ
Price updated Jun 19, 2026
AboutImmunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.Show more
- Revenue$0
- EBITDA-$532M-21.6%
- Net Income-$506M-22.2%
- EPS (Diluted)-2.77-1.5%
- ROE-64.82%-3.8%
IMVT Key Insights
Immunovant, Inc. (IMVT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 90 (top 10%)
- ✓Trading near 52-week high
✗Weaknesses
- ✗Profits declining 36.3% over 5 years
- ✗Weak Piotroski F-Score: 2/9
- ✗Shares diluted 20.4% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when IMVT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
IMVT Price & Volume
Immunovant, Inc. (IMVT) stock price & volume — 10-year historical chart
Loading chart...
IMVT Growth Metrics
Immunovant, Inc. (IMVT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-22.17%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-1.46%
Return on Capital
10 Years-56.07%
5 Years-55.11%
3 Years-63.17%
Last Year-68.29%
IMVT Recent Earnings
Immunovant, Inc. (IMVT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)
Q2 2026Latest
May 20, 2026Metric
Actual
Est
EPS
$0.73-23.3%
$0.59
Rev
—
—
Q1 2026
Feb 6, 2026Metric
Actual
Est
EPS
$0.61+15.3%
$0.72
Rev
—
$6M
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$0.73-1.4%
$0.72
Rev
—
—
Q3 2025
Aug 11, 2025Metric
Actual
Est
EPS
$0.60+13.0%
$0.69
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 20, 2026 | $0.73vs $0.59-23.3% | — |
| Q1 2026 | Feb 6, 2026 | $0.61vs $0.72+15.3% | —vs $6M |
| Q4 2025 | Nov 10, 2025 | $0.73vs $0.72-1.4% | — |
| Q3 2025 | Aug 11, 2025 | $0.60vs $0.69+13.0% | — |
Based on last 12 quarters of dataView full earnings history →
IMVT Peer Comparison
Immunovant, Inc. (IMVT) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ARDX | 1.48B | 6.05 | -23.27 | 22.09% | -13.58% | -38.11% | 1.27 | |
 RCUS | 2.45B | 24.31 | -7.39 | -4.26% | -156.36% | -68.97% | 0.16 | |
 VKTX | 3.52B | 30.38 | -9.52 | -71.31% | 0.00 | |||
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 DAWN | 2.22B | 21.53 | -20.70 | 20.6% | -67.85% | -23.43% | 0.01 | |
 ALXO | 82.97M | 1.53 | -0.81 | -124.06% | 0.20 | |||
 HALO | 8.13B | 68.55 | 26.78 | 37.55% | 23.13% | 126.27% | 43.89 | |
 UTHR | 22.78B | 536.59 | 19.26 | 10.61% | 40.61% | 19.24% |
Compare IMVT vs Peers
Immunovant, Inc. (IMVT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
IMVT Income Statement
Immunovant, Inc. (IMVT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - | - | - |
Cost of Goods Sold | 0 | 0 | 21K | 0 | 0 | 0 | 0 | 0 | 409K |
COGS % of Revenue | - | - | - | - | - | - | - | - | - |
Gross Profit | 0▲ 0% | 0▲ 0% | -21K▲ 0% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -409K▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | - | - |
Gross Profit Growth % | - | - | - | 100% | - | - | - | - | - |
Operating Expenses | 136.74M | 448 | 59.66M | 108.12M | 156.03M | 208.28M | 270.21M | 438.15M | 532.9M |
OpEx % of Revenue | - | - | - | - | - | - | - | - | - |
Selling, General & Admin | 1.48M | 448 | 11.73M | 39.51M | 54.23M | 48.02M | 57.28M | 77.23M | 76.24M |
SG&A % of Revenue | - | - | - | - | - | - | - | - | - |
Research & Development | 135.26M | 25.73M | 47.93M | 68.6M | 101.81M | 160.26M | 212.93M | 360.92M | 456.66M |
R&D % of Revenue | - | - | - | - | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Income | -136.74M▲ 0% | -450▲ 100.0% | -59.68M▼ 13261677.8% | -108.12M▼ 81.2% | -156.03M▼ 44.3% | -208.28M▼ 33.5% | -270.21M▼ 29.7% | -438.15M▼ 62.2% | -532.9M▼ 21.6% |
Operating Margin % | - | - | - | - | - | - | - | - | - |
Operating Income Growth % | - | 100% | -13261677.78% | -81.17% | -44.32% | -33.48% | -29.74% | -62.15% | -21.62% |
EBITDA | 0 | 9.55K | -59.66M | -108.05M | -155.91M | -208.08M | -269.98M | -437.77M | -532.49M |
EBITDA Margin % | - | - | - | - | - | - | - | - | - |
EBITDA Growth % | - | - | -624780.63% | -81.12% | -44.29% | -33.47% | -29.75% | -62.15% | -21.64% |
D&A (Non-Cash Add-back) | 136.74M | 10K | 21K | 65K | 126K | 193K | 231K | 377K | 409K |
EBIT | -136.74M | -448 | -65.67M | -108.12M | -156.03M | -208.28M | -270.21M | -438.15M | -532.9M |
Net Interest Income | 0 | 0 | -624.38K | 0 | 0 | -4.9M | 24.95M | 24.73M | 25.33M |
Interest Income | 0 | 0 | 625 | 0 | - | 7.58M | 24.95M | 24.73M | 25.33M |
Interest Expense | 0 | 0 | 625K | 0 | - | 12.48M | 0 | 0 | 0 |
Other Income/Expense | 116 | 0 | -6.61M | 328K | -781K | -2.67M | 11.44M | 25.2M | 27.51M |
Pretax Income | -136.74M▲ 0% | -448▲ 100.0% | -66.29M▼ 14796998.2% | -107.79M▼ 62.6% | -156.81M▼ 45.5% | -210.95M▼ 34.5% | -258.77M▼ 22.7% | -412.95M▼ 59.6% | -505.39M▼ 22.4% |
Pretax Margin % | - | - | - | - | - | - | - | - | - |
Income Tax | 0 | 0 | 97K | -358K | -84K | 9K | 567K | 891K | 215K |
Effective Tax Rate % | 0% | 0% | -0.15% | 0.33% | 0.05% | -0% | -0.22% | -0.22% | -0.04% |
Net Income | -136.74M▲ 0% | -448▲ 100.0% | -66.39M▼ 14818650.0% | -107.43M▼ 61.8% | -156.73M▼ 45.9% | -210.96M▼ 34.6% | -259.34M▼ 22.9% | -413.84M▼ 59.6% | -505.61M▼ 22.2% |
Net Margin % | - | - | - | - | - | - | - | - | - |
Net Income Growth % | - | 100% | -14818650% | -61.82% | -45.89% | -34.6% | -22.93% | -59.58% | -22.17% |
Net Income (Continuing) | -136.74M | -448 | -66.39M | -107.43M | -156.73M | -210.96M | -259.34M | -413.84M | -505.61M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -13.67▲ 0% | 0.00▲ 100.0% | -1.54▲ 0% | -1.22▲ 20.8% | -1.43▼ 17.2% | -1.71▼ 19.6% | -1.88▼ 9.9% | -2.73▼ 45.2% | -2.77▼ 1.5% |
EPS Growth % | - | 100% | - | 20.78% | -17.21% | -19.58% | -9.94% | -45.21% | -1.47% |
EPS (Basic) | -13.68 | 0.00 | -1.54 | -1.22 | -1.43 | -1.71 | -1.88 | -2.73 | -2.77 |
Diluted Shares Outstanding | 10M | 14.38M | 43.2M | 87.76M | 109.68M | 123.08M | 138.1M | 151.57M | 182.42M |
Basic Shares Outstanding | 10M | 14.38M | 43.2M | 87.76M | 109.68M | 123.08M | 138.1M | 151.57M | 182.42M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
IMVT Balance Sheet
Immunovant, Inc. (IMVT) balance sheet — assets, liabilities & shareholders' equity
| Metric | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 113.17K | 325K | 109.08M | 409.01M | 512.93M | 404.33M | 665.77M | 767.66M | 948.82M |
Cash & Short-Term Investments | 0 | 325K | 100.57M | 400.15M | 493.82M | 376.53M | 635.37M | 713.97M | 902.11M |
Cash Only | 0 | 325K | 100.57M | 400.15M | 493.82M | 376.53M | 635.37M | 713.97M | 902.11M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 0 | 3.04M | 1.14M | 12.86M | 885K | 5.5M | 2.51M | 3.95M |
Days Sales Outstanding | - | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 24.9M | 51.18M | 42.76M |
Total Non-Current Assets | 0 | 80K | 311K | 3.48M | 2.63M | 1.5M | 942K | 8.56M | 8.75M |
Property, Plant & Equipment | 0 | 0 | 65K | 3.48M | 2.63M | 1.5M | 595K | 942K | 515K |
Fixed Asset Turnover | - | - | - | - | - | - | - | - | - |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 79.95K | 246K | 0 | 0 | 0 | 0 | 7.62M | 7.68M |
Total Assets | 113.17K▲ 0% | 405K▲ 257.9% | 109.39M▲ 26909.1% | 412.49M▲ 277.1% | 515.56M▲ 25.0% | 405.84M▼ 21.3% | 666.71M▲ 64.3% | 776.22M▲ 16.4% | 957.57M▲ 23.4% |
Asset Turnover | - | - | - | - | - | - | - | - | - |
Asset Growth % | - | 257.87% | 26909.14% | 277.09% | 24.99% | -21.28% | 64.28% | 16.43% | 23.36% |
Total Current Liabilities | 1.61M | 380.45K | 15.32M | 18.77M | 44.52M | 43.3M | 48.61M | 68.78M | 104.42M |
Accounts Payable | 1.14M | 0 | 1.19M | 2.43M | 18.63M | 1.35M | 7.16M | 17.66M | 7.54M |
Days Payables Outstanding | - | - | 20.68K | - | - | - | - | - | 6.73K |
Short-Term Debt | 0 | 300K | 3.19M | 0 | 0 | 0 | 138K | 0 | 72K |
Deferred Revenue (Current) | 0 | -206 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | -206 | 10.94M | 3.14M | 171K | 350K | 26.57M | 15.62M | 80.04M |
Current Ratio | 0.07x | 0.85x | 7.12x | 21.79x | 11.52x | 9.34x | 13.70x | 11.16x | 9.09x |
Quick Ratio | 0.07x | 0.85x | 7.12x | 21.79x | 11.52x | 9.34x | 13.70x | 11.16x | 9.09x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 0 | 300K | 0 | 2.24M | 1.22M | 47K | 347K | 0 | 553K |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 2.24M | 1.22M | 47K | 0 | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 347K | 0 | 553K |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 1.61M | 380.45K | 15.32M | 21.01M | 45.74M | 43.34M | 48.95M | 68.78M | 104.97M |
Total Debt | 0 | 300K | 3.19M | 3.42M | 2.36M | 1.22M | 138K | 98K | 72K |
Net Debt | 0 | -25K | -97.38M | -396.73M | -491.45M | -375.31M | -635.23M | -713.87M | -902.04M |
Debt / Equity | - | 12.22x | 0.03x | 0.01x | 0.01x | 0.00x | 0.00x | 0.00x | 0.00x |
Debt / EBITDA | - | 31.41x | - | - | - | - | - | - | - |
Net Debt / EBITDA | - | -2.62x | - | - | - | - | - | - | - |
Interest Coverage | - | - | -105.07x | - | - | -16.69x | - | - | - |
Total Equity | -1.5M▲ 0% | 24.55K▲ 101.6% | 94.07M▲ 383041.9% | 391.48M▲ 316.2% | 469.82M▲ 20.0% | 362.49M▼ 22.8% | 617.76M▲ 70.4% | 707.45M▲ 14.5% | 852.59M▲ 20.5% |
Equity Growth % | - | 101.64% | 383041.9% | 316.16% | 20.01% | -22.84% | 70.42% | 14.52% | 20.52% |
Book Value per Share | -0.15 | 0.00 | 2.18 | 4.46 | 4.28 | 2.95 | 4.47 | 4.67 | 4.67 |
Total Shareholders' Equity | -1.5M | 24.55K | 94.07M | 391.48M | 469.82M | 362.49M | 617.76M | 707.45M | 852.59M |
Common Stock | 0 | 288 | 5K | 10K | 12K | 13K | 14K | 16K | 20K |
Retained Earnings | 0 | -448 | -91.23M | -198.66M | -355.39M | -566.35M | -825.68M | -1.24B | -1.75B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -1.5M | 343K | -16K | -298K | 404K | 852K | 1.91M | 1.46M | 730K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
IMVT Cash Flow Statement
Immunovant, Inc. (IMVT) cash flow — operating, investing & free cash flow history
| Metric | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -128.3M | -28.55M | -53.36M | -83.33M | -106.11M | -188.19M | -214.23M | -375.87M | -407.31M |
Operating CF Margin % | - | - | - | - | - | - | - | - | - |
Operating CF Growth % | - | 77.75% | -86.91% | -56.17% | -27.34% | -77.35% | -13.83% | -75.46% | -8.36% |
Net Income | -136.74M | -28.6M | -66.39M | -107.43M | -156.73M | -210.96M | -259.34M | -413.84M | -505.61M |
Depreciation & Amortization | 0 | 10K | 21K | 998K | 126K | 193K | 231K | 377K | 409K |
Stock-Based Compensation | 1.81M | 1.31M | 6.96M | 0 | 34.24M | 32.3M | 41.12M | 49.49M | 55.72M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 5.19M | -792K | 1.24M | 18.54M | 1.11M | 1.13M | 1.13M | 133K | 99K |
Working Capital Changes | 1.44M | -474K | 4.81M | 4.57M | 15.14M | -10.85M | 2.63M | -12.03M | 42.06M |
Change in Receivables | 0 | 0 | -83K | 2.5M | -11.72M | 12.22M | -4.56M | 2.97M | -1.4M |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 0 | 0 | 967K | 1.25M | 16.25M | -17.12M | 5.78M | 10.68M | -10.25M |
Cash from Investing | 0 | -52K | -31K | -210K | -254K | -197K | -360K | -759K | -8K |
Capital Expenditures | 0 | -52K | -31K | -210K | -254K | -197K | -360K | -759K | -8K |
CapEx % of Revenue | - | - | - | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 128.3M | 35.58M | 146.97M | 383.11M | 200.13M | 70.89M | 472.43M | 454.49M | 595.76M |
Debt Issued (Net) | 0 | 0 | 37.91M | -3.19M | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 0 | 0 | 0 | 386.3M | 0 | 70.5M | 472.75M | 450M | 596.26M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 128.3M | 35.58M | 109.07M | 0 | 200.13M | 385K | -318K | 4.49M | -504K |
Net Change in Cash | 0▲ 0% | 6.99M▲ 0% | 93.59M▲ 1239.8% | 299.57M▲ 220.1% | 93.67M▼ 68.7% | -117.28M▼ 225.2% | 258.83M▲ 320.7% | 78.61M▼ 69.6% | 188.14M▲ 139.3% |
Free Cash Flow | -128.3M▲ 0% | -28.6M▲ 77.7% | -53.39M▼ 86.7% | -83.54M▼ 56.5% | -106.37M▼ 27.3% | -188.39M▼ 77.1% | -214.59M▼ 13.9% | -376.63M▼ 75.5% | -407.32M▼ 8.1% |
FCF Margin % | - | - | - | - | - | - | - | - | - |
FCF Growth % | - | 77.71% | -86.68% | -56.47% | -27.33% | -77.11% | -13.91% | -75.52% | -8.15% |
FCF per Share | -12.83 | -1.99 | -1.24 | -0.95 | -0.97 | -1.53 | -1.55 | -2.48 | -2.23 |
FCF Conversion (FCF/Net Income) | 0.94x | 63720.98x | 0.80x | 0.78x | 0.68x | 0.89x | 0.83x | 0.91x | 0.81x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 61K | 0 | 0 | 0 | 509K | 1.2M | 2.39M |
IMVT Key Ratios
Immunovant, Inc. (IMVT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -1.82% | -141.11% | -44.25% | -36.39% | -50.69% | -52.91% | -62.46% | -64.82% |
Debt / Equity | - | 12.22x | 0.03x | 0.01x | 0.01x | 0.00x | 0.00x | 0.00x | 0.00x |
Interest Coverage | - | - | -105.07x | - | - | -16.69x | - | - | - |
FCF Conversion | 0.94x | 63720.98x | 0.80x | 0.78x | 0.68x | 0.89x | 0.83x | 0.91x | 0.81x |
Related:IMVT Dividend History·IMVT Revenue History·IMVT Price History·IMVT P/E History·IMVT Financial Ratios·IMVT Institutional Holders
IMVT SEC Filings & Documents
Immunovant, Inc. (IMVT) SEC filings — annual & quarterly reports (10-K, 10-Q)
IMVT Frequently Asked Questions
Immunovant, Inc. (IMVT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Immunovant, Inc. (IMVT) grew revenue by 0.0% over the past year. Growth has been modest.
Immunovant, Inc. (IMVT) reported a net loss of $505.6M for fiscal year 2026.
Dividend & Returns
Immunovant, Inc. (IMVT) has a return on equity (ROE) of -64.8%. Negative ROE indicates the company is unprofitable.
Immunovant, Inc. (IMVT) had negative free cash flow of $407.3M in fiscal year 2026, likely due to heavy capital investments.